PLX-038 is under clinical development by ProLynx and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PLX-038’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PLX-038 overview
PLX-038 is under development for the treatment of recurrent medulloblastoma, ependymoma, refractory or relapsed solid tumors including squamous non-small cell lung cancer, colorectal cancer, small cell lung cancer, triple-negative breast cancer (TNBC), ovarian cancer, peritoneal cancer, fallopian tube cancer and gastric cancer. It is administered through the intravenous route. It is a small molecule, long-acting, pegylated form of SN38. SN-38 is the active metabolite of the anti-cancer agent irinotecan (CPT-11). It acts by targeting topoisomerase 1. The drug candidate is developed based on the disruptive drug delivery system (DDS) technology.
ProLynx overview
ProLynx is a biotechnology company that has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company is headquartered in San Francisco, California, the US.
For a complete picture of PLX-038’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
